Podcasts about Pfizer

IN CLEAR FOCUS: Guest Robyn Jackson Malone, CEO of RJ Communications, joins us to discuss the increasingly important role of trust in health communications. Robyn argues that brands have a responsibility to fill the widening information gap authentically. She critiques "window dressing" diversity efforts, advocates for genuine equity, and highlights the critical role of patient advocacy. We also discuss the "You Don't Know Jack About MS" initiative and Pfizer's "I Can Do Both" campaign.

Waardeer je onze video's? Steun dan Café Weltschmerz, het podium voor het vrije woord: https://www.cafeweltschmerz.nl/doneren/Een openhartig gesprek met ondernemer en voormalig Europarlementariër Rob RoosLang keken we uit naar dit gesprek met Ros Roos, ex Europarlementariër, die op een moedige en doortastende manier de Covid-vaccinatie-leugen van Pfizer doorprikte. Dit live in een hoorzitting in het Europees Parlement met één van de topmensen van Pfizer. Wij blikken met hem terug over zijn strategie, zijn vastberadenheid en verlangen om de waarheid boven tafel te krijgen maar ook de prijs die hij daarvoor betaalde. Open en zonder omwegen vertelt hij over zijn gegroeide wantrouwen richting de overheid, de macht van instituties en de manier waarop volgens hem afwijkende meningen steeds minder ruimte krijgen.Rob deelt op emotionele wijze hoe de coronaperiode diepe sporen naliet, niet alleen politiek, maar ook persoonlijk en binnen zijn gezin. Hij beschrijft hoe besluiten en communicatie vanuit de overheid en de EU niet transparant zijn met een groeiend gebrek aan eerlijkheid en democratische controle. Volgens Roos leidde zijn onthulling van de waarheid in het parlement tot een botsing binnen zijn eigen partij JA 21 en uiteindelijk tot zijn vertrek.Dit gesprek gaat niet alleen over politiek, maar vooral over de mens achter de politicus: twijfel, loyaliteit, morele grenzen en de vraag wat het kost om trouw te blijven aan je overtuigingen wanneer je aan de kant wordt gezet.Een aflevering voor iedereen die wil begrijpen waarom het vertrouwen in de politiek afbrokkelt, en wat dat betekent voor onze samenleving en wat wij er als mensheid aan moeten doen.Abonneer je op ons kanaal voor meer diepgaande gesprekkenLaat in de reacties weten wat jij van dit gesprek vindt en Steun onze beweging via deze link: https://begrenzers.backme.org/---Deze video is geproduceerd door Café Weltschmerz. Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik dan op deze link: https://bit.ly/3XweTO0

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced.

Here's another one! I don't know if it's any good but the blurb seems interesting. Merry Christmas y'all. We thought that around now would be the time the antivax movement died. The data is clear - vaccines work. Not only that, but side effects are incredibly rare. Despite this, antivaxxers have simply lied their way through it - claiming that every heart attack is a result of the vaccines and pushing conspiracy theories alongside any celebrity death they can. With the 'revelation' that Pfizer didn't test for transmission in the clinical trials (clinical trials that antivaxxers previously denied ever happened) we have seen yet another perceived victory for these idiots, with many of them expecting some form of apology. I'm sorry you're an idiot? Will that do?Jack looks at the data - and we discuss the bad faith argument put forward as a result of this honest answer from a pfizer exec being conned by an antivax snake. Published 28th Oct 2022.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

About Bari Kowal:Bari Kowal is a senior biopharmaceutical executive with over 30 years of experience leading global operations, clinical development, and strategic portfolio management. As Senior Vice President at Regeneron, she oversees development operations, enterprise-wide portfolio strategy, risk management, and major technology initiatives, helping guide the company's continued growth and innovation. Her career spans leadership roles at Pfizer, ICON Clinical Research, Valera Pharmaceuticals, PDL BioPharma, GenVec, and Covance, where she built high-performing teams and drove operational excellence across clinical operations and strategic programs. Bari also serves on the Board of Directors of TransCelerate BioPharma Inc., contributing to industry-wide efforts to streamline and strengthen clinical trial execution. She is known for her governance expertise, collaborative leadership style, and ability to deliver organizational transformation at scale. Bari holds a master's degree in neuroscience from New York University, with additional academic training from the University of Pennsylvania and Binghamton University.Things You'll Learn:Expanding access to clinical trials requires educating both patients and physicians, many of whom are unfamiliar with how to engage in research. Better awareness can dramatically increase participation and diversify trial populations.Technology alone will not speed up drug development unless systems are connected end-to-end. Interoperability is the real catalyst for reducing inefficiencies across discovery, development, and regulatory submission.Clean, structured data is the foundation of meaningful AI adoption in healthcare. Without it, predictive models and trial optimization tools cannot reach their potential.Trial complexity is one of the most significant barriers to faster development timelines. Streamlining procedures, reducing unnecessary tests, and learning from regulatory feedback can significantly accelerate progress.Sustainable clinical research requires equipping trial sites with greater capacity and support. Even when the right patients are identified, sites must be capable of enrolling and managing them effectively.Resources:Connect with and follow Bari Kowal on LinkedIn.Follow Regeneron on LinkedIn and visit their website.

Audio roundup of selected biopharma industry content from Scrip over the business week ended December 19, 2025. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Regeneron caught between success and expiry; Q3's top 10 drugs; Lilly's Retatrutide Raises Weight-Loss Bar; Pfizer stands by vaccines investment; and Sanofi Upbeat Despite Tolebrutinib Tribulations. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-XA4W4OYCVRCSNHW5ZL7TUFJF2U/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

Send us a textEpisode 142 of the Joint Dynamics Podcast JD host Andrew Cox | Joint Dynamics features Mariano García-Valiño. Mariano is a four-time health-tech entrepreneur and CEO of Axenya, a company revolutionizing healthcare with AI, advanced software, data science, and human-centered support. Mariano has led the creation, scaling, and exit of major companies including a $9 billion sale and a $1 billion IPO, with earlier roles at Pfizer, Lilly, McKinsey, and global investment firms. Beyond his business acumen, Mariano supports his drive and innovative mindset via his dedication to meditation and his work as an experimental art photographer, blending creativity and mindfulness to fuel his leadership. He is also the Amazon #1 bestselling author of "INEDIBLE," which explores why healthcare lags in technology adoption and how to fix it. Mariano holds an Engineering degree from Universidad de Buenos Aires and an MBA from Harvard Business School earned on a Fulbright Scholarship, underscoring his diverse expertise in entrepreneurship, technology, and human-centered innovation.Quick recap*Show sponsor is Muvitality Medicinal Mushrooms for modern day health and wellness | Mu …Go to muvitality.com and use the code JD10 to receive a 10% discount on your purchase of Mu Functional mushrooms such as Lions Mane, Cordyceps, Chaga, Reishi, and Turkey tail functional mushroomsEnjoyHere are some useful links for this podcastMariano's Book - Software is eating the world, yet healthcare remains INEDIBLE: How to Build the Modern, Tech-Enabled, Healthcare Experience - https://www.amazon.com/Software-eating-healthcare-remains-INEDIBLE-ebook/dp/B0FVGLQ1QF?ref_=ast_author_dp&th=1&psc=1www.mgarciavalino.comRelevant episodesEpisode 122 - Dr Christine Houghton on Genetics, Nutritional Biochemistry & Sulforaphane https://podcasts.apple.com/hk/podcast/episode-122-dr-christine-houghton-on-genetics-nutritional/id1527374894?i=1000699475907JOINT DYNAMICS links:Joint Dynamics Facebook - https://www.facebook.com/JointDynamicsHongKong/Joint Dynamics Instagram -https://www.instagram.com/jointdynamics/Joint Dynamics Youtube - https://www.youtube.com/channel/UCRQZplKxZMSvtc6LxM5WckwJoint Dynamics Website - www.jointdynamics.com.hk Host - Andrew Cox - https://www.jointdynamics.com.hk/the-team/trainers/andrew-cox

GLP-1 drugs have become one of the most important developments in the pharmaceutical industry. With products like Ozempic, Wegovy, and Mounjaro in high demand, competition between drug makers is growing quickly. In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 inhibitors — the drugs behind today's weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. Their discussion also looks at a major recent development: Pfizer's acquisition of biopharma startup Metsera, and why this deal could significantly change the market. Skip and Dez's conversation gives listeners a clear and practical introduction to competition and strategy in the pharmaceutical industry — while helping you improve your Business English. In this episode, you will learn: What GLP-1 drugs are and what they are used for. The main differences between Ozempic, Wegovy, Mounjaro, and Zepbound. Why Eli Lilly is gaining market share, especially in North America. How Pfizer's acquisition could affect future weight-loss treatments. Do you like what you hear? Become a D2B Member today for to access to our -- NEW!!!-- interactive audio scripts, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes. Visit d2benglish.com/membership for more information. Follow Down to Business English on Apple podcasts, rate the show, and leave a comment. Contact Skip, Dez, and Samantha at downtobusinessenglish@gmail.com Follow Skip & Dez Skip Montreux on Linkedin Skip Montreux on Instagram Skip Montreux on Twitter Skip Montreux on Facebook Dez Morgan on Twitter RSS Feed

SimplySafeDividends just downgraded a major pharmaceutical stock with a 7% dividend yield. I break down why this dividend freeze could signal a cut ahead. Watch the YouTube video.In this video, I cover:-Why Pfizer's dividend freeze is the first warning sign (first since 2009)-How "accidentally high yields" indicate danger, not opportunity-The 97% free cash flow payout ratio leaves no margin for error-Declining revenue and the $17-18B patent cliff ahead-What dividend investors should look for to avoid dividend trapsThis is NOT a prediction that Pfizer will cut - it's an educational analysis of the risk factors every dividend investor should understand. Learn how to spot warning signs before they become dividend cuts.Dapper Dividends Recommendation Tracker Spreadsheet⁠Check out my current portfolio on

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Support Viva: GET MERCH! www.vivafrei.com BUY A BOOK! https://amzn.to/4qBXikS SEND ME SOMETHING! David Freiheit 20423 SR 7 Ste F6319 Boca Raton 33498 TIP WITH CTYPTO! bc1qt0umnqna63pyw5j8uesphsfz0dyrtmqcq5ugwm THAT IS ALL!

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe New Confederacy Has a Star and Crescent //  Trump Pushes Drugs  // “Expert on “White, Christian Nationalism” Says “Black Christian Nationalism is Fine.Episode links:  Former TSA agent says she remembers millions of dollars in cash being flown out of Minneapolis St. Paul International AirportPalestinian Islamic scholar in Chicago, Mohammad Nusairat: “We did not come here to coexist. We are superior to everyone else and will not be surpassed. No one is above us. If other religions want to live with us, they have to worship Allah.”Minneapolis Police Chief on ICE detaining illegals:  “Mary and Joseph themselves were considered outsiders and forced to stay in a barn.”Trump DOJ seeks to quash Pfizer whistleblower's lawsuit over COVID shots; The Justice Department attorney did not mention the Trump FDA's recent admission linking the COVID shots to at least 10 child deaths so far.Leftists uniquely target white Christians.

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe New Confederacy Has a Star and Crescent //  Trump Pushes Drugs  // “Expert on “White, Christian Nationalism” Says “Black Christian Nationalism is Fine.Episode Links:Trump DOJ seeks to quash Pfizer whistleblower's lawsuit over COVID shots; The Justice Department attorney did not mention the Trump FDA's recent admission linking the COVID shots to at least 10 child deaths so far. BOMBSHELL: SENATOR JOHNSON JUST REVEALED THE DATA THEY HID: Senator Ron Johnson has now stated—on record—that federal health officials knowingly concealed vaccine risk signals instead of warning the public.MIC DROP: RFK Jr. shuts down reporter's ridiculous appeal to authority.OFFIT: “With the mRNA vaccines, there was myocarditis which is inflammation of the heart muscle … That was a very small price to pay … People have to have realistic expectations of the fact that you're going to learn as you go.”"Human cells are meant to make human proteins, not to make toxins."Dr. Ryan Cole, MD Pathologist - "To inject a gene-based product into the body & make your cells the factory for a toxin is PSYCHOLOGICALLY INSANE."

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

About Mary Varghese Presti:Mary Varghese Presti is a transformational healthcare leader with over two decades of experience spanning clinical care, federal reform, biopharma, and health technology. As Corporate Vice President of Microsoft Health & Life Sciences, she drives growth in complex environments by creating clear strategy, aligning organizations, and operationalizing execution with discipline. Her prior roles include leading Nuance's Dragon Medical business, overseeing IBM Watson Health's Life Sciences portfolio, incubating new ventures at athenahealth, and driving digital-health transformation at Pfizer. She began her career as a pediatric nurse at Johns Hopkins and later helped shape national health IT and payment reforms at Booz Allen. Known for navigating complexity with optimism and rigor, she consistently turns ambiguity into strategy and strategy into measurable results.Things You'll Learn:AI in healthcare is evolving from simple assistants to agentic services that can independently execute predictable workflows, allowing clinicians to regain time and focus. This shift enables a hybrid workforce where human and digital colleagues work side by side.Dragon Copilot for nurses was designed specifically to support the way nurses document care, capturing structured inputs such as vitals, intake/output, and observations through natural speech. By reducing EHR time and ambiently recording bedside interactions, it helps turn “caring out loud” into complete documentation.Nurses spend more than a quarter of their 12-hour shifts documenting in the EHR, often feeling emotionally torn between screens and patients. AI that listens in the background can significantly reduce this burden while allowing for more presence at the bedside.New tools are starting to expose the “invisible work” nurses perform, from constant micro-assessments to coordination with ancillary departments. Making this work visible is a critical step toward properly valuing nursing labor and improving workforce planning.Real-world use cases, such as AI agents assembling data for tumor boards at academic centers, show that agentic workflows can compress decision timelines from weeks to days. These same principles can be extended to many clinical and non-clinical tasks, accelerating care while preserving clinician judgment.Resources:Connect with and follow Mary Varghese Presti on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft and Life Sciences website.Listen to Mary's previous interview on our podcast here.Watch Mary's keynote presentation at the HLTH conference here.

In Episode 33, Dr. Aly-Khan Lalani and Dr. Christoper Wallis sit down with Dr. Daniel Heng, Clinical Professor at the University of Calgary and Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre. Together, they explore the full landscape of mentorship and sponsorship in academic medicine, from what makes an exceptional mentee to how leaders identify and support rising talent.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/17/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v70yuz6","div":"rumble_v70yuz6"}); Video Source Links (In Chronological Order): Support The Last American Vagabond Trump EPA Nearly Doubles Threshold for Safe Formaldehyde Exposure — ProPublica Susie Wiles, Trump's Chief of Staff, Criticizes Bondi and Vance in Candid Interviews - The New York Times New Tab (5) Mehdi (e/λ) on X: "I believe DARPA just launched the most audacious bioengineering program of the decade & nobody's talking about it loud enough I spent hours reading through the Generative Optogenetics program documentation & honestly I'm still processing the implications of what they're trying https://t.co/1Uh0VsUz8F" / X GO: Generative Optogenetics | DARPA Generative Optogenetics (GO) Overview - YouTube New Tab DARPA 'Generative Optogenetics (GO)' Seeks to Program Living Cells Using Light, Could Aid in 'Extended Human Spaceflight' Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives - PMC Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy | Nature Communications News: Optogenetics and mRNA Vaccines Net... (The Scientist) - Behind the headlines - NLM Optogenetics: We may soon be able to manipulate the mind with light - Genetic Literacy Project Coronavirus Gives a Dangerous Boost to DARPA's Darkest Agenda New Tab Can Magnetism Help Us Control the Brain, Remotely? - University at Buffalo Magnetogenetics and the Future of Remote Biological Control RFK Jr. wants everyone to use wearables. What are the benefits, risks? - ABC News Evaluating methods and protocols of ferritin-based magnetogenetics - ScienceDirect Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates | bioRxiv Flipping a Switch Inside the Head - Seek : Seek Genetically engineered 'Magneto' protein remotely controls brain and behaviour | Science | The Guardian The field of neurogenetics: where it stands and where it is going - PMC Biodigital Convergence, COVID Magnetogenetic Ferritin Vaccines & Big Spikes In Mass Vaccinated Areas Bob Langer The Coronavirus "Common Denominator" Tied To Charles Lieber & Israel's NY "Smart Cities" Charles Lieber's nanoscale transistors can enter cells without harming them | Harvard Magazine Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | Pfizer (8) John Beaudoin, Sr., The Real CdC, The Last Boomer on X: "Please repost How can they just ignore 18,000 kidney deaths in ONE state? @zoeharcombe @_Esther4_14 @Earthdriver @unhealthytruth @elonmusk @EmeraldRobinson @jqe22 @CartlandDavid @GenFlynn @thevivafrei @RobertKennedyJr @JimFergusonUK @LizGunnNZ @FluoridePoison @RepMTG" / X Trump Admin Leans Into Self-Amplifying mRNA (SamRNA) Under Guise Of Ending mRNA & RNA In Food New Tab (8) The Last American Vagabond on X: "With the #6G news, be sure to read @DBrozeLiveFree's article breaking down what this really means & how little they care about the health & environmental side effects—in fact they have baked into their bills that these factors cannot even be considered. https://t.co/ZNwOTZhMEy" / X Trump's FCC Seeks to Strip Even More Local Control Over 5G Rollout (8) ADAM on X: "BREAKING:

In this short episode of Let's Combinate: Drugs + Devices, Subhi Saadeh breaks down ICH Q13 and what “continuous manufacturing” actually means. He compares batch vs. continuous, explains how a batch still exists in continuous manufacturing, and covers the essentials quality teams care about: RTD/traceability, control strategy, and disturbances/diversion plus a quick high-level note on validation, release, and lifecycle.Timestamps00:00 Intro01:00 Batch vs. continuous (and batch definition)03:00 Modes of continuous manufacturing (ICH Q13 examples)04:30 RTD & traceability06:00 Control strategy07:30 Disturbances & diversion09:00 Validation / release / lifecycle (high level)10:00 Wrap-upSubhi Saadeh is the Founder and Principal of Let's Combinate BioWorks and host of the Let's Combinate: Drugs + Devices podcast/Youtube Channel. With experience across Quality, Manufacturing Commercialization, Sustaining and R&D, Subhi has helped industrialize and launch drug delivery systems for biologics, vaccines, and generics at leading organizations such as Pfizer, Gilead, and Baxter. Subhi focuses on bridging the disconnect between drug and device development and specializes in harmonizing internal systems, aligning internal and external partners, and helping combination product teams move from siloed execution to scalable, compliant, and patient-ready solutions. He currently chairs the Rx-360 Combination Product Working Group and was the International WG Chair at the Combination Product Coalition. He has contributed to global harmonization efforts through BIO, ASTM, and AAMI. He is a certified ISO13485 Lead Auditor, CQA and CQE.For questions, inquiries, or suggestions, please reach out at letscombinate.com or on the show's LinkedIn Page.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über ein Ausnahmejahr für Rückversicherer, einen Dämpfer für Rüstungsaktien und Enttäuschung bei Pfizer. Außerdem geht es um Rheinmetall, Renk, Hensoldt, Lufthansa, Easyjet, Warner Bros Discovery, Paramount Skydance, Netflix Pfizer, Moderna, Biontech, Tilray Brands, Swiss Re, Munich Re, Hannover Rück, iShares S&P 500 Insurance ETF (WKN: A0H08K), Rize USA Environmental Impact UCITS ETF (WKN: A3ENMA), iShares MSCI Climate Transition Aware UCITS ETF (WKN: 906866), Lyxor MSCI Green Infrastructure ETF (WKN: LYX0YL), VanEck Sustainable Infrastructure ETF (WKN: A12HWR), Teva Pharmaceutical, Bank Leumi, Bank Hapoalim, Elbit Systems und Check Point Software. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos Pfizer schrumpft. Kraft Heinz spaltet mit neuem CEO. Ölpreis und Rüstungsaktien sinken. DroneShield steigt. Apple expandiert iPhone-Kollektion. Fonds wollen kein Cash. Ford will keine E-Autos. Arbeitsmarkt in USA ist durchwachsen. Eine KI-Wette mit Dividende und ohne Rechenzentren? C.H. Robinson (WKN: A0HGF5) macht's möglich. Killt KI die Werbeagenturen? Börse denkt: Nein. Wir denken: Es kommt drauf an. Publicis (WKN: 859386), WPP (WKN: A1J2BZ). CoreWeave (WKN: A413X6) fährt einen heißen Reifen. Früher hat's die Börse geliebt. Jetzt hasst sie es. Was wir außerdem spannend finden: Technische Stärke und Starkregen in Texas. Diesen Podcast vom 17.12.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center. Today I am excited to be joined by Dr. Shilpa Gupta, Director of Genitourinary Medical Oncology at the Cancer Institute and co-leader of the GU Oncology Program at the Cleveland Clinic, and also lead author of the JCO PO article titled "Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma." At the time of this recording, our guest's disclosures will be linked in the transcript. Shilpa, welcome again to the podcast. Thank you for joining us today. Dr. Shilpa Gupta: Thank you, Rafeh. Honor to be here with you again. Dr. Rafeh Naqash: It is nice to connect with you again after two years, approximately. I think we were in our infancy of our JCO PO podcast when we had you first time, and it has been an interesting journey since then. Dr. Shilpa Gupta: Absolutely. Dr. Rafeh Naqash: Well, excited to talk to you about this article that you published. Wanted to first understand what is the genomic landscape of urothelial cancer in general, and why should we be interested in FGFR3 alterations specifically? Dr. Shilpa Gupta: Bladder cancer or urothelial cancer is a very heterogeneous cancer. And while we find there is a lot of mutations can be there, you know, like BRCA1, 2, in HER2, in FGFR, we never really understood what is driving the cancer. Like a lot of old studies with targeted therapies did not really work. For example, we think VEGF can be upregulated, but VEGF inhibitors have not really shown definite promise so far. Now, FGFR3 receptor is the only therapeutic target so far that has an FDA approved therapy for treating metastatic urothelial cancer patients, and erdafitinib was approved in 2019 for patients whose tumors overexpressed FGFR3 mutations, alterations, or fusions. And in the landscape of bladder cancer, it is important because in patients with non-muscle invasive bladder cancer, about 70 to 80% patients can have this FGFR3. But as patients become metastatic, the alterations are seen in, you know, only about 10% of patients. So the clinical trials that got the erdafitinib approved actually used archival tumor from local cancer. So when in the real world, we don't see a lot of patients if we are trying to do metastatic lesion biopsies. And why it is important to know this is because that is the only targeted therapy available for our patients right now. Dr. Rafeh Naqash: Thank you for giving us that overview. Now, on the clinical side, there is obviously some interesting data for FGFR3 on the mutation side and the fusion side. In your clinical practice, do you tend to approach these patients differently when you have a mutation versus when you have a fusion? Dr. Shilpa Gupta: We can use the treatment regardless of that. Dr. Rafeh Naqash: I recently remember I had a patient with lung cancer, squamous lung cancer, who also had a synchronous bladder mass. And the first thought from multiple colleagues was that this is metastatic lung. And interestingly, the liquid biopsy ended up showing an FGFR3-TACC fusion, which we generally don't see in squamous lung cancers. And then eventually, I was able to convince our GU colleagues, urologists, to get a biopsy. They did a transurethral resection of this tumor, ended up being primary urothelial and synchronous lung, which again, going back to the FGFR3 story, I saw in your paper there is a mention of FGFR3-TACC fusions. Anything interesting that you find with these fusions as far as biology or tumor behavior is concerned? Dr. Shilpa Gupta: We found in our paper of all the patients that were sequenced that 20% had the pathognomonic FGFR3 alteration, and the most common were the S249C, and the FGFR3-TACC3 fusion was in 45 patients. And basically I will say that we didn't want to generate too much as to fusion or the differences in that. The key aspect of this paper was that historically there were these anecdotal reports saying that patients who have FGFR alterations or mutations, they may not respond well to checkpoint inhibitors because they have the luminal subtype. And these were backed by some preclinical data and small anecdotal reports. But since then, we have seen that, and that's why a lot of people would say that if somebody's tumor has FGFR3, don't give them immunotherapy, give them erdafitinib first, right? So then we had this Phase 3 trial called the THOR trial, which actually showed that giving erdafitinib before pembrolizumab was not better. That debunked that myth, and we are actually reiterating that because in our work we found that patients who had FGFR3 alterations or fusions, and if they also have TMB-high, they actually respond very well to single agent immunotherapy. And that is, I think, very important because it tells us that we are not really seeing that so-called potential of resistance to immunotherapy in these patients. So to answer your question, yeah, we did see those differences, but I wouldn't say that any one marker is more prominent. Dr. Rafeh Naqash: The analogy is kind of similar to what we see in lung cancer with these mutations called STK11/KEAP1, which are also present in some other tumors. And one of the questions that I don't think has been answered is when you have in lung cancer, if you extrapolate this, where doublet or single agent immunotherapy doesn't do as well in tumors that are STK11 mutated. But then if you have a high TMB, question is does that TMB supersede or trump the actual mutation? Could that be one reason why you see the TMB-high but FGFR3 altered tumors in your dataset responding or having better outcomes to immunotherapy where potentially there is just more neoantigens and that results in a more durable or perhaps better response to checkpoint therapy? Dr. Shilpa Gupta: It could be. But you know, the patients who have FGFR alterations are not that many, right? So we have already seen that just patients with TMB-high respond very well to immunotherapy. Our last podcast was actually on that, regardless of PD-L1 that was a better predictor of response to immunotherapy. So I think it's not clear if this is adding more chances of response or not, because either way they would respond. But what we didn't see, which was good, that if they had FGFR3, it's not really downplaying the fact that they have TMB-high and that patients are not responding to immunotherapy. So we saw that regardless, and that was very reassuring. Dr. Rafeh Naqash: So if tomorrow in your clinic you had an individual with an FGFR3 alteration but TMB-high, I guess one could be comfortable just going ahead with immunotherapy, which is what the THOR trial as you mentioned. Dr. Shilpa Gupta: Yes, absolutely. And you know, when you look at the toxicity profiles of pembrolizumab and erdafitinib, really patients really struggle with using the FGFR3 inhibitors. And of course, if they have to use it, we have to, and we reserve it for patients. But it's not an easy drug to tolerate. Currently the landscape is such that, you know, frontline therapy has now evolved with an ADC and immunotherapy combinations. So really if patients progress and have FGFR3 alterations, we are using erdafitinib. But let's say if there were a situation where a patient has had chemotherapy, no immunotherapy, and they have FGFR3 upregulation and TMB-high, yes, I would be comfortable with using only pembrolizumab. And that really ties well together what we saw in the THOR trial as well. Dr. Rafeh Naqash: Going to the clinical applications, you mentioned a little bit of this in the manuscript, is combination therapies. You alluded to it a second back. Everything tends to get combined with checkpoint therapy these days, as you've seen with the frontline urothelial, pembrolizumab with an ADC. What is the landscape like as far as some of these FGFR alterations are concerned? Is it reasonable to combine some of those drugs with immune checkpoint therapy? And what are some of the toxicity patterns that you've potentially seen in your experience? Dr. Shilpa Gupta: So there was indeed a trial called the NORSE trial. It was a randomized trial but not a comparative cohort, where they looked at FGFR altered patients. And when they combined erdafitinib plus cetrelimab, that did numerically the response rates were much higher than those who got just erdafitinib. So yeah, the combination is definitely doable. There is no overlapping toxicities. But unfortunately that combination has not really moved forward to a Phase 3 trial because it's so challenging to enroll patients with such kind of rare mutations on large trials, especially to do registration trials. And since then the frontline therapy has evolved to enfortumab vedotin and pembrolizumab. I know there is an early phase trial looking at a next generation FGFR inhibitor. There is a triplet combination looking in Phase 1 setting with a next generation FGFR inhibitor with EV-pembro. However, it's not a randomized trial. So you know, I worry about such kinds of combinations where we don't have a path for registration. And in the four patients that have been treated, four or five patients in the early phase as a part of basket trial, the toxicities were a lot, you know, when you combine the EV-pembro and an FGFR3 inhibitor, we see more and more toxicity. So the big question is do we really need the "kitchen sink" approach when we have a very good doublet, or unless the bar is so high with the doublet, like what are we trying to add at the expense of patient toxicity and quality of life is the big question in my mind. Dr. Rafeh Naqash: Going back to your manuscript specifically, there could be a composite biomarker. You point out like FGFR in addition to FGFR TMB ends up being predictive prognostic there. So that could potentially be used as an approach to stratify patients as far as treatment, whether it's a single agent versus combination. Maybe the TMB-low/FGFR3 mutated require a combination, but the TMB-high/FGFR mutated don't require a combination, right? Dr. Shilpa Gupta: No, that's a great point, yeah. Dr. Rafeh Naqash: But again, very interesting, intriguing concepts that you've alluded to and described in this manuscript. Now, a quick take on how things have changed in the bladder cancer space in the last two years. We did a podcast with you regarding some biomarkers as you mentioned two years back. So I really would like to spend the next minute to two to understand how have things changed in the bladder cancer space? What are some of the exciting things that were not there two years back that are in practice now? And how do you anticipate the next two years to be like? Maybe we'll have another podcast with you in another two years when the space will have changed even more. Dr. Shilpa Gupta: Certainly a lot has happened in the two years, you know. EV-pembro became the universal frontline standard, right? We have really moved away from cisplatin eligibility in metastatic setting because anybody would benefit from EV-pembro regardless of whether they are candidates for cisplatin or not, which historically was relevant. And just two days ago, we saw that EV-pembro has now been approved for localized bladder cancer for patients who are cisplatin ineligible or refusing. So, you know, this very effective regimen moving into earlier setting, we now have to really think of good treatment options in the metastatic setting, right? So I think that's where a lot of these novel combinations may come up. And what else we've seen is in a tumor agnostic trial called the DESTINY-PanTumor trial, patients who had HER2 3+ on immunohistochemistry, we saw the drug approval for T-DXd, and I think that has kind of reinvigorated the interest in HER2 in bladder cancer, because in the past targeting HER2 really didn't work. And we still don't know if HER2 is a driver or not. And at ESMO this year, we saw an excellent study coming out of China with DV which is targeting HER2, and toripalimab, which is a Chinese checkpoint inhibitor, showing pretty much similar results to what we saw with EV-pembro. Now, you know, not to do cross-trial comparisons, but that was really an amazing, amazing study. It was in the presidential session. And I think the big question is: does that really tell us that HER2-low patients will not benefit? Because that included 1+, 2+, 3+. So that part we really don't know, and I think we want to study from the EV-302 how the HER2 positive patients did with EV and pembro. So that's an additional option, at least in China, and hopefully if it gets approved here, there is a trial going on with DV and pembro. And lastly, we've seen a very promising biomarker, like ctDNA, for the first time in bladder cancer in the adjuvant setting guiding treatment with adjuvant atezolizumab. So patients who were ctDNA positive derived overall survival and recurrence-free survival benefit. So that could help us select moving forward with more studies. We can spare unnecessary checkpoint inhibitors in patients who are not going to benefit. So I think there is a lot happening in our field, and this will help do more studies because we already have the next generation FGFR inhibitors which don't have the toxicities that erdafitinib comes with. And combining those with these novel ADCs and checkpoint inhibitors, you know, using maybe TMB as a biomarker, because we really need to move away from PD-L1 in bladder cancer. It's shown no utility whatsoever, but TMB has. Dr. Rafeh Naqash: Well, thank you so much, Shilpa, for that tour de force of how things have changed in bladder cancer. There used to be a time when lung and melanoma used to lead this space in terms of the number of approvals, the biomarker development. It looks like bladder cancer is shifting the trend at this stage. So definitely exciting to see all the new changes that are coming up. I'd like to spend another minute and a half on your career. You've obviously been a leader and example for many people in the GU space and beyond. Could you, for the sake of our early career especially, the trainees and other listeners, describe how you focused on things that you're currently leading as a leader, and how you shaped your career trajectory over the last 10 years? Dr. Shilpa Gupta: That's a really important question, Rafeh, and you and I have had these discussions before, you know, being an IMG on visas like you, and being in different places. I think I try to make the most of it, you know, instead of focusing on the setbacks or the negative things. Like tried to grab the opportunities that came along. When I was at Moffitt, got to get involved with the Phase 1 trial of pembrolizumab in different tumor types. And just keeping my options open, you know, getting into the bladder cancer at that time when I wanted to really do only prostate, but it was a good idea for me to keep my options open and got all these opportunities that I made use of. I think an important thing is to, like you said, you know, have a focus. So I am trying to focus more on biomarkers that, you know, we know that 70% patients will respond to EV-pembro, right? But what about the remaining 30%? Like, so I'm really trying to understand what determines hyperprogressors with such effective regimens who we really struggle with in the clinic. They really don't do well with anything we give them after that. So we are doing some work with that and also trying to focus on PROs and kind of patient-reported outcomes. And a special interest that I've now developed and working on it is young-onset bladder cancer. You know, the colorectal cancer world has made a lot of progress and we are really far behind. And bladder cancer has historically been a disease of the elderly, which is not the case anymore. We are seeing patients in their 30s and 40s. So we launched this young-onset bladder cancer initiative at a Bladder Cancer Advocacy Network meeting and now looking at more deep dive and creating a working group around that. But yeah, you know, I would say that my philosophy has been to just take the best out of the situation I'm in, no matter where I am. And it has just helped shape my career where I am, despite everything. Dr. Rafeh Naqash: Well, thank you again. It is always a pleasure to learn from your experiences and things that you have helped lead. Appreciate all your insights, and thank you for publishing with JCO PO. Hopefully we will see more of your biomarker work being published and perhaps bring you for another podcast in a couple of years. Dr. Shilpa Gupta: Yeah, thank you, Rafeh, for the opportunity. And thanks to JCO PO for making these podcasts for our readers. So thanks a lot. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Shilpa Gupta Stock and Other Ownership Interests: Company: BioNTech SE,  Nektar Consulting or Advisory Role: Company: Gilead Sciences, Pfizer, Merck, Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, AstraZeneca, Novartis, Johnson & Johnson/Janssen Research Funding: Recipient: Your Institution Company: Bristol Myers Squibb Foundation, Merck, Roche/Genentech, EMD Serono, Exelixis, Novartis, Tyra Biosciences, Pfizer, Convergent Therapeutics, Acrivon Therapeutics, Flare Therapeutics, Amgen Travel, Accommodations, Expenses: Company: Pfizer, Astellas Pharma, Merck    

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

Former Pfizer Head Exposes Covid Tyranny, Reveals Jabs Were Bioweapon Meant To Maim, Kill & Sterilize Population! Pentagon Begins Process Of Court-Martialing Sen. Kelly

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to employment data that had been delayed due to the government shutdown. Job creation in November was stronger than expected, but the unemployment rate rose last month to 4.6%— and October payrolls showed a shedding of jobs. National Economic Council Director Kevin Hassett joined the program with White House reaction to the data. He and the anchors also discussed Hassett in the running to become Fed chair, Fed rate policy and inflation, growth prospects for 2026 and the AI boom. Also in focus: Ford's $19.5 billion hit and EV pullback, Pfizer full-year guidance disappoints, the AI trade and a flashback with CoreWeave's CEO, Comcast update. Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC. Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

En el boletín de hoy también hablamos de: ⚖️ Pfizer bajo lupa: ¿todos recibieron lo mismo? Soros, censura digital y nuevas leyes desde Europa. Rebelión del campo: el modelo agrario estalla. España quiere vetar redes sociales a menores. ️ ¿Motos en peligro? DGT anticipa restricciones. Tu cuerpo como fuente de energía. Queremos saber tu opinión: ¿Aceptas que te quiten opciones de movilidad y comunicación en nombre de tu propio bien? Comparte si sientes que el control avanza disfrazado de progreso. #MindaliaDespierta #Pfizer #ControlDigital #LibertadDeExpresion #Censura #SoberaniaAlimentaria #Agricultores #ActualidadConsciente

Welcome back, everyone, to another episode of Aigoracast. Our guest today is Todd Renn, a distinguished leader in consumer insights and sensory science with over 25 years of experience driving innovation at industry giants like PepsiCo, Pfizer, Clorox, and Land O'Lakes. Holding a PhD in food science and advanced credentials in business analytics from UT Austin and Wharton, Todd excels at bridging the gap between R&D and marketing, turning complex data into clear, actionable business stories. Now the founder of Todd Renn and Associates, he is dedicated to helping organizations sharpen their commercial impact and training sensory scientists to evolve into strategic business partners.

Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On the latest BioCentury This Week podcast, BioCentury's analysts break down last week's readouts from Eli Lilly, Structure  and Wave Life Sciences, and discuss a deal in the space by Pfizer.Lilly reported the latest for its triple agonist contender retatrutide for best-in-class weight loss, while strong Phase IIb data put Structure back in the oral GLP-1 race. Meanwhile, Pfizer added an oral GLP-1R agonist via a deal). Structure and Wave parlayed their data into follow-on cash, as did Kymera after posting data for its STAT6 program KT-621 that hints at a new era for degraders in immunology.The analysts then detailed the results of BioCentury's industry sentiment survey on FDA, which found that politicization of the agency's leadership, volatility and uncertainty are casting a long shadow over investor and drug developer sentiment. Finally, they discuss the impact of the congressional stalemate over the U.S. Small Business Innovation Research (SBIR) program.View full story: https://www.biocentury.com/article/657880#ObesityDrugDevelopment #TargetedProteinDegradation #STAT6 #FDARegulation #SBIRFunding00:00 - Introduction01:45 - Obesity Data12:17 - Kymera's Breakthrough21:45 - FDA Survey Results29:41 - SBIR Funding StalemateTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

A $19.5 billion charge will hit Ford's (F) balance sheet in regards to the legacy automaker's EV business. Diane King Hall explains why the company is making a strategy pivot and how Ford expects outlook to improve despite the charge. Pfizer's (PFE) guidance wasn't rosy as COVID product sales continue to decline. Lockheed Martin (LMT) faced pressure from a Morgan Stanley downgrade. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

In this episode of The Future of Work® Podcast, we sit down with Selena Rezvani — internationally known leadership speaker, TEDx presenter, LinkedIn Top Voice, and bestselling author of Quick Confidence and Quick Leadership. Selena shares practical tools for transforming traditional leadership into a more human, trust-based practice. Drawing on her work with organizations like Microsoft, Pfizer, and The World Bank, she offers powerful strategies for empowering employees, creating psychologically safe teams, and cultivating inclusion across generations. From ditching bossware to encouraging self-advocacy, this conversation is a must-listen for leaders navigating the new era of hybrid work, shifting generational values, and the mental health crisis impacting today's workforce. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into the latest breakthroughs, regulatory updates, and industry trends shaping the future of healthcare.Let's start with Johnson & Johnson's recent achievement in precision oncology. They've secured a second FDA approval for Akeega, a combination therapy that merges J&J's Zytiga with GSK's Zejula. This innovative approach targets BRCA2-mutated metastatic castration-sensitive prostate cancer, marking a significant advancement in personalized medicine. This approval not only highlights the progress in tailored treatment strategies but also sets a new benchmark for therapeutic innovation in this particular cancer subset.Moving on to cardiovascular health, Cincinnati's LIB Therapeutics has introduced Lerochol, a third-generation PCSK9 inhibitor designed to lower cholesterol. Unlike its predecessors, Lerochol offers simplified administration, potentially improving patient adherence and outcomes. This approval is part of a broader effort to refine lipid-lowering therapies and better address cardiovascular diseases.In a groundbreaking development for heart rhythm disorders, Milestone Pharmaceuticals has received FDA approval for Cardamyst, a nasal spray that patients can self-administer to manage paroxysmal supraventricular tachycardia (PSVT). This novel treatment option empowers patients with an on-demand solution to control their heart rhythms, significantly enhancing their quality of life.Turning to infectious diseases, Innoviva's Nuzolvence has been approved as a much-needed new treatment for gonorrhea, the first in over three decades following GSK's Blujepa. This marks an essential step forward in combating antibiotic-resistant sexually transmitted infections and highlights the urgency of developing new antimicrobial agents.However, not all ventures have met with success. Argenx recently halted studies of its drug Vyvgart in thyroid eye disease after disappointing trial results. This decision underscores the inherent challenges and risks involved in drug development, particularly when tackling complex autoimmune conditions.Sanofi has faced its own hurdles with Tolebrutinib after experiencing both FDA delays and trial misses in non-relapsing secondary progressive multiple sclerosis. These setbacks emphasize the intricacies of bringing innovative therapies to market and the critical importance of robust clinical trial design and regulatory strategy.Strategic collaborations are also playing a pivotal role in the industry. Adaptive Biotechnologies has partnered with Pfizer to leverage its T-cell receptor discovery technology. Meanwhile, Dren Bio is expanding its collaboration with Sanofi to develop next-generation B-cell depleting therapies for autoimmune diseases. These alliances reflect an increasing trend towards collaborative innovation to harness cutting-edge technologies.Another strategic move comes from Sobi, which has acquired Arthrosi Therapeutics for $950 million to bolster its portfolio with phase 3 gout treatments. This acquisition bypasses traditional IPO routes and showcases evolving deal-making strategies within biopharma.In another exciting development, Kyverna Therapeutics is on the verge of securing the first-in-class CAR-T therapy approval for autoimmune diseases following promising trial results with its CD19 agent. This could herald a new era in autoimmune disease management through cellular therapies.In regulatory news beyond pharmaceuticals, former President Donald Trump signed an executive order establishing a unified federal framework for artificial intelligence (AI). This aims to streamline AI regulation across states and could accelerate AI integration into various sectors, including healthcare.These developments collectively represent pivotal moments in the pharmaceutical and Support the show

The Weekly Option trading podcast Episode 405 December 13, 2025 Welcome to The Weekly Option, a weekly program that offers practical trades and discussion for beginners and professionals alike. The topic of the week is sandbagging your numbers. In this week's show, we will cover the trades from last week on iRobot Corp, USA Rare Earth, Pfizer, and Him & Hers Inc. And we discuss four new trades on Plug Power Inc, Richtech Robotics Inc, Alcoa Corp, and Barrick Mining Corp. The US market spent the week anticipating and then digesting the quarter basis point reduction in the interest rate announced on Wednesday by the Federal Reserve Bank. The Dow Jones Industrial Average grew 503 points, closing at 48,458 points. The S&P 500 Index lost 42 points, ending the week at 6,827 points. It's always great to hear from listeners. If you have any questions about the trades presented here or about your own positions, feel free to email me. Email questions to me: eric@theweeklyoption.com Visit our YouTube Channel for The Weekly Option.com. PODCAST LINKS FOR EPISODE POST Listen on iTunes:  https://itunes.apple.com/us/podcast/the-weekly-option/id1375267155 Listen on YouTube Music:  https://music.youtube.com/channel/UCTo2yTkZPhqvlE8PdZkyTZA Listen on Spotify: https://open.spotify.com/show/6HoYh2XxVCWaidJP4dJiSD Listen on Audible by Amazon: https://www.audible.com/podcast/The-Weekly-Option/B08K57QL6S?language=en_US Listen on PodBean: https://www.podbean.com/podcast-detail/r5aam-6a884/The-Weekly-Option-Podcast YouTube Channel: https://goo.gl/u7JKJd Option Trading Basics: My Favorite Strategies: https://youtu.be/8UmPK5tuez0 How to Trade Stock Using Technical Analysis: https://youtu.be/wAATt0RpE0w Technical Analysis Videos: https://www.youtube.com/channel/UCnpPLl3EB_RBC5kyrCnsHow TradingView Stock Charts For Analysis: https://www.tradingview.com/gopro/?share_your_love=TraderEric

In this episode of Dividend Talk, we're joined by Niklas from Heavy Moat Investments for a deep dive into European small- and mid-cap investing, moats, portfolio concentration, and how to think about quality businesses when valuations get stretched.We kick things off with a packed dividend roundup, covering recent dividend hikes from Broadcom, Mastercard, Abbott Labs, Eli Lilly, WD-40, Zoetis, and more, with a strong focus on why healthcare has been so active lately. We also discuss Pfizer keeping its dividend flat, and what that signals for big pharma investors.From there, we look at one of the biggest European investing stories of the week: Aegon moving its headquarters to the US. We break down what this means for European capital markets, valuation multiples, and whether companies leaving Europe is a symptom of deeper structural issues.The core of the episode is our conversation with Niklas, where we explore:What a “moat” really means — and why moats are not staticHow he evaluates small and mid-cap European companiesWhy insider ownership matters more than market capHis approach to portfolio concentration vs diversificationHow he uses hurdle rates, expected IRR, and quality scoringWhen and why he decides to sell a stockWe also discuss several real-world examples, including:InPost and the rise of parcel locker networks across EuropeEVS Broadcast, a Belgian hidden champion in live sports technologyMensch und Maschine, Autodesk reselling, proprietary software, and dividend sustainabilityEdenred, regulation risk, shareholder yield, and why pessimism may be overdoneEurofins Scientific as a long-term compounder with strong capital allocationTo wrap up, we answer listener questions on:Story vs fundamentalsThe biggest financial red flags to watch forAI in investing and portfolio analysisThe “right” number of stocks in a portfolioSmall-cap investing in Europe vs the USAs always, this episode is for entertainment purposes only and should not be considered financial advice.Useful links: Continue the conversation with our community at ⁠⁠⁠⁠Facebook ⁠⁠or ⁠⁠⁠⁠Discord⁠⁠⁠20 Deep Dives a Year &Library of 150 EU & US Dividend stocks at ⁠⁠⁠https://www.dividendtalk.euHeavy Moat Investments | Substack

How do you transform a simple vision into a brand that attracts opportunities and solves real problems? Jason Feifer, editor-in-chief turned media mogul, is here to share the blueprint with every aspiring entrepreneur and keynote speaker. In this episode, he shares his transformational journey from media insider to personal brand powerhouse. While serving as an editor, Jason realized that he wasn't just the guy behind the magazine; he was an authority waiting to be discovered. This realization sparked a career reinvention, where he redefined his personal brand and built a media company that empowers others.  Jason now advises top entrepreneurs and speaks globally, showing how the right mindset and strategic thinking can unlock endless opportunities. From embracing your "5% character" to understanding the importance of building your own media, Jason shares valuable lessons on how to build a personal brand that stands out in a crowded digital landscape. "The most successful people are the most adaptable. They develop a unique personal relationship with change that enables them to grow, build, and thrive while everything else swirls around them. " ~ Jason Feifer In This Episode: - Meet Jason Feifer - From media insider to building a personal brand - Cold pitching lessons from pitching the media - Understanding AI's role in media and business - What the most successful people do differently - Jason's theory of experience and "one thing" concept - Building a scalable keynote and product-market fit - AI's impact on the future of personal branding and social media - Final advice on building a strong personal brand and business - Where to find Jason online About Jason Feifer: Jason Feifer is the editor in chief of Entrepreneur magazine, a startup advisor, keynote speaker, and a widely recognized authority on business and communications. Jason regularly speaks for the world's greatest companies and organizations, and has given keynotes for Google, Clorox, Pfizer, Microsoft, Alibaba, Crocs, and more.  He's also the co-founder of CPG Fast Track, a private network for early-stage consumer packaged goods founders. He writes a newsletter called One Thing Better, and co-hosts the podcast Help Wanted with best-selling money expert Nicole Lapin. LinkedIn named him a “Top Voice in Entrepreneurship“. Website: https://www.jasonfeifer.com/  Instagram: https://www.instagram.com/heyfeifer/  Newsletter: https://www.jasonfeifer.com/newsletter/            Where to find me: IG: https://www.instagram.com/jen_gottlieb/    TikTok: https://www.tiktok.com/@jen_gottlieb     Facebook: https://www.facebook.com/Jenleahgottlieb    Website: https://jengottlieb.com/    My business: https://www.superconnectormedia.com/     YouTube: https://www.youtube.com/@jen_gottlieb

Neoborn Caveman hosts a heartfelt, pro-humanity interview with Shanna Carroll, a grieving Michigan mother who shares the unimaginable loss of her vibrant 17-year-old daughter Aubrynn Shay Grundy—diagnosed with COVID-19, myocarditis, and multi-organ failure just weeks after her second Pfizer vaccine in June 2022—recounting the family's desperate fight against hospital protocols like remdesivir and ventilators, the chilling dismissal of vaccine injury possibilities by doctors, and Shanna's quest for truth amid suppressed stories, all while blending holiday warmth with calls for accountability in a system that prioritizes narratives over lives.Key TakeawaysParental intuition battles institutional denial.Vaccine mandates eclipse individual risks.Hospital treatments can accelerate suffering.Grief fuels advocacy for hidden truths.Family bonds endure beyond medical failures.Transparency saves future generations.Human rights demand questioning authority.Sovereignty includes bodily choice.Stories of loss must break silence.Healing comes through shared vulnerability.Sound Bites"She received her vaccinations on June 7 and June 28, 2022. Other than some arm soreness, she had no symptoms initially.""She had been selected for a school trip... and it was mandatory for her to be vaccinated.""Her death certificate listed COVID-19 and multi-organ failure as cause of death.""People's stories are suppressed, she said, but they all need to be heard."Gather for unfiltered rambles (and extended interviews like this) at patreon.com/theneoborncavemanshow free join, chats, lives.keywords: vaccine injury, Aubrynn Grundy, Shanna Carroll, myocarditis, remdesivir, parental grief, medical accountability, COVID mandates, human rights, suppressed storiesHumanity centered satirical takes on the world & news + music - with a marble mouthed host.Free speech marinated in comedy.Supporting Purple Rabbits. Hosted on Acast. See acast.com/privacy for more information.

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Sponsor: GET SOME GOLD! Go to https://goldsafeexchange.com/viva-frei-rumble-audience/#form & claim an additional $1,500 in FREE gold or silver with qualifying purchases

What if students saw themselves not just as learners, but as world builders, empowered to design, problem-solve, and imagine new possibilities through playful learning? In this episode of the Fueling Creativity in Education Podcast, hosts Dr. Cindy Burnett and Dr. Matthew Warwood dive into the dynamic potential of game-based learning and world-building with guests Stephen Slota and Trent Hergenrader. Together, they unpack how treating students as designers—rather than passive recipients of information—fosters creativity, critical thinking, and authentic engagement. Drawing from their experiences as educators and co-authors of The World Building Workshop, Stephen Slota and Trent Hergenrader share insights on leveraging narrative, choice, and playful contexts to deepen learning, regardless of technology access or subject area. The conversation explores the difference between true game-based learning and surface-level gamification, emphasizing the power of agency, narrative, and exploring “messy,” real-world problems. Listeners will gain practical insights on aligning classroom activities with learning goals, infusing creativity, and adopting a facilitator mindset. Whether you're game-curious or an experienced educator, this episode highlights how world building can transform classrooms—and help students make meaningful connections to their own lives.   Guest Bios Stephen Slota Stephen Slota is an educational technologist, learning theorist, and interactive storyteller. He has directed major projects for organizations like CVS Health, Pfizer, and Arizona State University, where he explores how game mechanics and narratives can enhance engagement, creativity, and learning. A former high school biology teacher, Stephen Slota draws on years of classroom experience and research at the University of Connecticut to promote playful learning as a transformative tool in education.   Trent Hergenrader Trent Hergenrader is an Associate Professor of English and Creative Writing, and Director of the Center for World Building and Storytelling at Rochester Institute of Technology. He's the co-editor of "Creative Writing in the Digital Age" and "Creative Writing Innovations," and author of "Collaborative World Building for Writers and Gamers." Trent Hergenrader integrates fiction writing, role-playing, and collaborative design to help students view learning as a creative, participatory process. For more resources and to connect with the guests, visit theworldbuildingworkshop.com.   Be sure to subscribe on your favorite platform and sign up for our Extra Fuel newsletter for more resources and inspiration. Visit FuelingCreativityPodcast.com for more information or email us at questions@fuelingcreativitypodcast.com.

This episode was recorded for my UK Column show.Mike Yeadon is a former Vice President and Chief Scientific Officer for allergy and respiratory research at Pfizer, where he spent 16 years developing new medicines before founding his own biotech company, Ziarco.With a PhD in pharmacology and over 30 years in pharmaceutical research, Mike became one of the most prominent voices challenging the official Covid narrative. He was amongst the first credentialed scientists to call out the government's 'lethally incompetent' scientific advice, arguing that lockdowns were based on flawed PCR testing that produced massive numbers of false positives.Mike consistently warned that the so-called 'second wave' was fabricated through dodgy testing protocols, pointing out that respiratory deaths in late 2020 were actually lower than in previous years. His outspoken criticism of the experimental Covid injections—which he argued were 'toxic by design' and failed to prevent illness or transmission—led to widespread censorship across social media platforms.➡️ Mike's Substack

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

America Out Loud PULSE with Dr. Clayton J. Baker – I step away from geoengineering to expose Pfizer's mRNA influenza trial and the troubling data omissions buried within it. By examining expert analysis, I reveal Big Pharma's familiar playbook of manipulation. This moment signals a larger breaking point, where truth becomes the tool to confront vaccine deception and the broader globalist agenda...

The Nurses of America Out Loud with David, Nicole & Ashley - Of people who get the flu, most never enter the healthcare system, and among those who do, many are vaccinated. When we hear “it was only 40% effective last year,” that itself is already wildly manipulative. A lot of people are going to think that means their absolute risk of getting the flu will be lowered by 40%....

The Nurses of America Out Loud with David, Nicole & Ashley - Of people who get the flu, most never enter the healthcare system, and among those who do, many are vaccinated. When we hear “it was only 40% effective last year,” that itself is already wildly manipulative. A lot of people are going to think that means their absolute risk of getting the flu will be lowered by 40%....

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/5/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v70gta2","div":"rumble_v70gta2"}); Video Source Links (In Chronological Order): (26) Brook Jackson

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci